Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

L. Bhatt, Deepak; Szarek, Michael; Gabríel Steg, Philippe; P. Cannon, Christopher; A. Leiter, Lawrence; K. McGuire, Darren; B. Lewis, Julia; C. Riddle, Matthew; A. Voors, Adriaan; Metra, Marco; H. Lund, Lars; Komajda, Michel; M. Testani, Jeffrey; S. Wilcox, Christopher; Ponikowski, Piotr; D. Lópes, Renato; Verma, Subodh; Lapuerta, Pablo; Pitt, Bertram

doi:10.1056/nejmoa2030183

Public

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Published in New England Journal of Medicine • Nov 16, 2020

Authors:

Deepak L. Bhatt

Michael Szarek

Philippe Gabríel Steg

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated ...

Subject

Heart failure

Diabetes mellitus

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!